Skip to content
JCP
PCC
News
CME
About
Authors
Sign In
Subscribe
Search
Advanced Search
Menu
JCP
PCC
News
CME
About
Authors
Sign In
Subscribe
Clinical Topics
View All
Depression
Neurologic
Anxiety
Schizophrenia
Trauma
Psychopharmacology
Bipolar
Tardive Dyskinesia
OCD
Addiction
View All
Columns
View All
ASCP Corner
Clinical & Practical Psychopharmacology
Rounds General Hospital
Academic Highlights
Banner Alzheimer’s Institute
Focus on Geriatric Psychiatry
Bernard L. Silverman, MD
JCP
Original Research
Olanzapine Plus Samidorphan in Schizophrenia With AUD
March 10, 2020
Alcohol use disorder is comorbid in 33% of US patients with schizophrenia. Testing the tolerability of olanzapine and samidorphan until the first event of exacerbation of disease symptoms is...
Mary F. Brunette
,
Christoph U. Correll
,
Stephanie S. O' Malley
, et al
JCP
Original Research
Olanzapine/Samidorphan for Schizophrenia
March 3, 2020
Read a study evaluating the antipsychotic efficacy and safety of OLZ/SAM compared with placebo in patients with an acute exacerbation of schizophrenia.
Steven G. Potkin
,
Jelena Kunovac
,
Bernard L. Silverman
, et al
JCP
Original Research
Metabolic Effects of Aripiprazole Lauroxil
November 23, 2016
Aripiprazole lauroxil, a long-acting injectable antipsychotic, demonstrated safety and efficacy in treating schizophrenia symptoms in a recent RCT. But how does it stack up against other antipsychotics in terms...
Henry A. Nasrallah
,
John W. Newcomer
,
Robert Risinger
, et al
JCP
Original Research
A Randomized, Double-Blind, Placebo-Controlled Trial of Aripiprazole Lauroxil in Acute Exacerbation of Schizophrenia
August 26, 2015
Herbert Y. Meltzer
,
Robert Risinger
,
Henry A. Nasrallah
, et al
JCP
Original Research
Early Treatment Response in Alcohol Dependence With Extended-Release Naltrexone
February 14, 2008
Domenic A. Ciraulo
,
Qunming Dong
,
Bernard L. Silverman
, et al